Combination Use of CD47 Antibodies/Inhibitors with Sorafenib for Treatment of Liver Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 16, 2017
app pub date -
Sep 16, 2015
filing date -
Sep 16, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The subject invention pertains to methods, and related compositions, for treating or inhibiting liver cancer, comprising administering an effective amount of sorafenib; and an inhibiting agent selected from a CD47 inhibiting agent, a NF-κB inhibiting agent, and combination thereof.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully